CTLA4 and gastric cancer: Blocking the programmed cell death (PD)-1 protein, its ligand (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) was reported to achieve durable responses in advanced gastric cancer patients (Figure 1) [10,11,12,13,14,15].